RhumbLine Advisers’s ALX Oncology ALXO Stock Holding History
Bought
Maintained
Sold
Other funds holding ALXO
RhumbLine Advisers's ALXO Position: Q3 2026 in Review
RhumbLine Advisers increased its ALX Oncology (ALXO) stake by 36% in Q3 2026, buying an estimated $75.5K and bringing the position to 147,003 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #3260.
RhumbLine Advisers first reported a position in ALXO in Q3 2020 and has held it in 21 quarters since. The position peaked at $1.35M in Q1 2021. 112 funds tracked by Wall St. Rank hold ALXO as of Q3 2026.
- RhumbLine Advisers held 147,003 shares of ALX Oncology worth $204K as of Q3 2026.
- RhumbLine Advisers bought 39,101 ALX Oncology shares in Q3 2026, an estimated $75.5K.
- ALX Oncology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3260 holding.
- RhumbLine Advisers first reported a position in ALX Oncology in Q3 2020 and has held it in 21 quarters since.
- RhumbLine Advisers's ALX Oncology position peaked at $1.35M in Q1 2021.
- 112 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.